NAV

Diclazuril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Diclazuril
DrugBank Accession Number
DB11398
Background

Diclazuril is a coccidiostat.

Type
Small Molecule
Groups
Investigational, Vet approved
Structure
3D
Similar Structures
Weight
Average: 407.64
Monoisotopic: 405.9791086
Chemical Formula
C17H9Cl3N4O2
Synonyms
  • Diclazuril
  • Diclazurilo
  • Diclazurilum
External IDs
  • DRG-0079
  • P-64433
  • R-64-433
  • R-64433
  • R64,433
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Clinacox

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylacetonitriles. These are cyclic aromatic compounds containing a diphenylacetonitrile moiety, which consists of a diphenylmethane linked to and acetonitrile to form 2,2-diphenylacetonitrile.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylacetonitriles
Direct Parent
Diphenylacetonitriles
Alternative Parents
Diphenylmethanes / Dichlorobenzenes / Aryl chlorides / 1,2,4-triazines / Heteroaromatic compounds / Lactams / Nitriles / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
1,2,4-triazine / 1,3-dichlorobenzene / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Carbonitrile / Chlorobenzene / Diphenylacetonitrile / Diphenylmethane
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
K110K1B1VE
CAS number
101831-37-2
InChI Key
ZSZFUDFOPOMEET-UHFFFAOYSA-N
InChI
InChI=1S/C17H9Cl3N4O2/c18-10-3-1-9(2-4-10)12(7-21)16-13(19)5-11(6-14(16)20)24-17(26)23-15(25)8-22-24/h1-6,8,12H,(H,23,25,26)
IUPAC Name
2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazin-2-yl)phenyl]acetonitrile
SMILES
ClC1=CC=C(C=C1)C(C#N)C1=C(Cl)C=C(C=C1Cl)N1N=CC(=O)NC1=O

References

General References
  1. Menichetti F, Moretti MV, Marroni M, Papili R, Di Candilo F: Diclazuril for cryptosporidiosis in AIDS. Am J Med. 1991 Feb;90(2):271-2. [Article]
  2. Kayembe K, Desmet P, Henry MC, Stoffels P: Diclazuril for Isospora belli infection in AIDS. Lancet. 1989 Jun 17;1(8651):1397-8. [Article]
  3. Vanparijs O, Hermans L, Marsboom R: Anticoccidial efficacy of diclazuril in partridges. Vet Rec. 1991 Oct 12;129(15):339-40. [Article]
  4. Vanparijs O, Hermans L, Marsboom R: Anticoccidial efficacy of diclazuril in pheasants. Vet Rec. 1990 Apr 7;126(14):332-3. [Article]
  5. Lindsay DS, Rippey NS, Toivio-Kinnucan MA, Blagburn BL: Ultrastructural effects of diclazuril against Toxoplasma gondii and investigation of a diclazuril-resistant mutant. J Parasitol. 1995 Jun;81(3):459-66. [Article]
  6. Lindsay DS, Rippey NS, Blagburn BL: Treatment of acute Toxoplasma gondii infections in mice with diclazuril or a combination of diclazuril and pyrimethamine. J Parasitol. 1995 Apr;81(2):315-8. [Article]
  7. Peeters JE, Geeroms R: Efficacy of diclazuril against robenidine resistant Eimeria magna in rabbits. Vet Rec. 1989 Jun 3;124(22):589-90. [Article]
  8. De Kock J, De Smet M, Sneyers R: Determination of diclazuril in animal feed by liquid chromatography. J Chromatogr. 1992 Jul 31;606(1):141-6. [Article]
  9. Vanparijs O, Hermans L, Marsboom R: Efficacy of diclazuril against Eimeria dispersa in turkeys. Avian Dis. 1991 Jul-Sep;35(3):599-600. [Article]
  10. Vanparijs O, Hermans L, Van der Flaes L, Marsboom R: Efficacy of diclazuril against turkey coccidiosis in dose-titration studies. Avian Dis. 1989 Jul-Sep;33(3):422-4. [Article]
KEGG Drug
D03794
ChemSpider
401855
BindingDB
50088493
RxNav
1368201
ChEBI
95118
ChEMBL
CHEMBL284733
Wikipedia
Diclazuril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentCryptosporidiosis infection / Human Immunodeficiency Virus (HIV) Infections2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00267 mg/mLALOGPS
logP4.09ALOGPS
logP4.23Chemaxon
logS-5.2ALOGPS
pKa (Strongest Acidic)6.5Chemaxon
pKa (Strongest Basic)-9.3Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area85.56 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity98.07 m3·mol-1Chemaxon
Polarizability37.18 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-001i-0397000000-0e08dc88a42e413750ce
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0002900000-19f5be62e6ff385006f5
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0009000000-936755679c5395356f79
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0049000000-cbfb6f78b658b26cf058
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-006t-0091000000-49927893ec77b288542e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0079-0390000000-f30860756ac10cf48ba6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0f79-0920000000-249408083c15561d5b67
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0079300000-e98ef7de288e67f2726c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0000900000-8d2d6cda6df99849f471
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0000900000-70b05ae21a85d95519d8
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0003900000-541c8d66ce2fd65948dc
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0zgl-5009500000-741f735ff24984b62250
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-057r-1009000000-ea1f16cf4f7f8fcbb0c9
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001l-9000000000-6bc5fca14c78b7d7d0c6
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-185.49843
predicted
DeepCCS 1.0 (2019)
[M+H]+187.85641
predicted
DeepCCS 1.0 (2019)
[M+Na]+194.55367
predicted
DeepCCS 1.0 (2019)

Drug created at February 25, 2016 18:24 / Updated at February 21, 2021 18:53